A Phase I/IIa Double-Blind, Randomized, Placebo-controlled Dose-Finding Study to Evaluate the Safety and Immunogenicity of AERAS-456 in HIV-Negative Adults With and Without Latent Tuberculosis Infection
Phase of Trial: Phase I/II
Latest Information Update: 29 Jan 2016
At a glance
- Drugs H56IC (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors Aeras
- 04 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 12 Nov 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Aug 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.